Data standards in drug discovery: A long way to go.

Jens M Kelm¹, Marc Ferrer², Martin-Immanuel Bittner³, Madhu Lal-Nag⁴

¹Precomb Therapeutics AG, Hombrechtikon, Switzerland. Electronic address: jens.kelm@precomb.com.

²Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Rockville, MD, USA.

³Arctoris Ltd, Oxford, UK; Young Academy of the German National Academy of Sciences, Berlin, Germany.

⁴InSphero AG, Schlieren, Switzerland.

PubMed DOI

Abstract

Each year, millions to trillions of data points are generated to evaluate the response of chemicals and biologicals to human cells in vitro and in vivo using various technologies and endpoints. Despite the vast amount of data available, the development process has not become significantly more efficient in recent years. Given the increasing use of more complex physiological models, which are time-…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.